Literature DB >> 1316674

Structure and pathogenicity of individual variants within an immunodeficiency disease-inducing isolate of FeLV.

J Overbaugh1, E A Hoover, J I Mullins, D P Burns, L Rudensey, S L Quackenbush, V Stallard, P R Donahue.   

Abstract

We previously described the molecular cloning of a replication-defective variant of feline leukemia virus (FeLV) that induced fatal immunodeficiency in cats. Eighteen proviruses have now been molecularly cloned from cats inoculated with the original isolate (FeLV-FAIDS) or its in vivo passages. Three were replication-competent and each of these was noncytopathic for the feline T-cell line, 3201. Replication of the prototype, FeLV-61E, in cats was associated with development of T cell tumors in some cats. The remaining 15 proviruses were replication-defective, but each of six of these tested was found to be cytopathic for 3201 cells when rescued with the noncytopathic helper virus, 61E. Three defective/helper virus mixtures were inoculated into cats and all induced fatal immunodeficiency, but with varied efficiency and kinetics. Each of these virus mixtures was attenuated relative to a mixture containing 61E and the intestine-targeted, FeLV-FAIDS-61C prototype defective molecular clone. Furthermore, one replication-competent virus chimera generated using the envelope and LTR of the defective pathogenic variant was incapable of inducing viremia in cats. The observed differences in the biological activity between the defective viruses could be attributed to no more than 10 scattered amino acid changes in envelope and either one or two nucleotide changes in the LTR.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316674     DOI: 10.1016/0042-6822(92)90510-v

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Evolution of broad host range in retroviruses leads to cell death mediated by highly cytopathic variants.

Authors:  G Jonah A Rainey; John M Coffin
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Feline leukemia virus envelope sequences that affect T-cell tropism and syncytium formation are not part of known receptor-binding domains.

Authors:  S R Gwynn; F C Hankenson; A S Lauring; J L Rohn; J Overbaugh
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Differential pathogenicity of two feline leukemia virus subgroup A molecular clones, pFRA and pF6A.

Authors:  A J Phipps; H Chen; K A Hayes; P Roy-Burman; L E Mathes
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Specificity in receptor usage by T-cell-tropic feline leukemia viruses: implications for the in vivo tropism of immunodeficiency-inducing variants.

Authors:  A S Lauring; M M Anderson; J Overbaugh
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 5.  Endogenous env elements: partners in generation of pathogenic feline leukemia viruses.

Authors:  P Roy-Burman
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

Review 6.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

7.  Delayed cytopathicity of a feline leukemia virus variant is due to four mutations in the transmembrane protein gene.

Authors:  E Thomas; J Overbaugh
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

8.  Generation and role of defective proviruses in cytopathic feline leukemia virus (FeLV-FAIDS) infections.

Authors:  C M de Noronha; T A Reinhart; J I Mullins
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Pathogenicity induced by feline leukemia virus, Rickard strain, subgroup A plasmid DNA (pFRA).

Authors:  H Chen; M K Bechtel; Y Shi; A Phipps; L E Mathes; K A Hayes; P Roy-Burman
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

10.  Interference with superinfection and with cell killing and determination of host range and growth kinetics mediated by feline leukemia virus surface glycoproteins.

Authors:  B S Kristal; T A Reinhart; E A Hoover; J I Mullins
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.